Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

695
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
695
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensitivity of clinician-assessed efficacy outcome measurement instruments in trials of topical therapies for atopic dermatitis: a systematic review and meta-analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

[Embolization of splenic artery aneurysms: Treatment of choice. About a case and review of the literature].

Annales de cardiologie et d'angeiologie·2020
Same author

Update of inflammatory proliferative retinopathy: Ischemia, hypoxia and angiogenesis.

Current research in translational medicine·2019
Same author

Immunohistochemical and genetic exploration of incompatible A blood group antigen expression in invasive micropapillary breast carcinoma: A case report.

Current research in translational medicine·2017
Same author

Distinctive roles of PKC delta isozyme in platelet function.

Current research in translational medicine·2016
Same author

Solanapyrones, Phytotoxins Produced by Alternaria solani: Biosynthesis and Isolation of Minor Components.

Bioscience, biotechnology, and biochemistry·2016

Related Experiment Video

Updated: Mar 31, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.7K

PKCs in thrombus formation.

Y Zaid1, N Senhaji2, A Naya3

  • 1Laboratory of Thrombosis and Hemostasis, Montreal Heart Institute, 5000 Belanger, Montreal, H1T 1C8 Quebec, Canada.

Pathologie-Biologie
|October 19, 2015
PubMed
Summary

Protein kinase C (PKC) isoforms differentially regulate platelet activation and thrombus formation. Understanding these roles is crucial for developing targeted therapies for thrombotic disorders.

Keywords:
AggregationAgrégationPKCPlaquettePlateletThrombus

More Related Videos

The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
05:46

The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

387
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.4K

Related Experiment Videos

Last Updated: Mar 31, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.7K
The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
05:46

The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

387
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.4K

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • The protein kinase C (PKC) family plays a critical role in regulating platelet activation.
  • Different PKC isoforms exhibit varied functions, acting as positive or negative regulators of platelet responses.
  • Agonist type and concentration influence the specific role of each PKC isoform.

Purpose of the Study:

  • To review and synthesize recent findings on the involvement of individual PKC isoforms in platelet activation.
  • To elucidate the specific roles of PKCα, PKCθ, PKCδ, PKCβ, and PKCɛ in platelet signaling and thrombus formation.

Main Methods:

  • Literature review of studies investigating PKC isoforms in platelet function.
  • Analysis of in vivo and in vitro experimental data on platelet aggregation and thrombus formation.
  • Examination of molecular interactions involving PKC isoforms and signaling pathways.

Main Results:

  • PKCα deficiency significantly reduces in vivo thrombus formation.
  • PKCθ knockout inhibits platelet aggregation in response to PAR4.
  • PKCδ, in complex with Fyn, inhibits platelet aggregation.
  • PKCβ interacts with RACK1, influencing αIIbβ3 signaling.
  • PKCɛ is involved in platelet function downstream of GPVI.

Conclusions:

  • Individual PKC isoforms have distinct and complex roles in regulating platelet activation and thrombus development.
  • Targeting specific PKC isoforms may offer therapeutic strategies for modulating platelet function in thrombotic diseases.